



03-~~8~~-02

7730110

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Simon LeMaire, et al.)
Serial No.: 10/068,905) Attorney Docket:
Filed: February 7, 2002) 86366
For: HISTOGRANIN-LIKE PEPTIDES AND) Art Group:
NON-PEPTIDES, PROCESSES FOR THEIR) Not yet assigned
PREPARATION AND USES THEREOF)
Examiner: Not yet assigned)

REPLY UNDER 37 C.F.R. 1.821(g) INCLUDING
STATEMENTS UNDER 37 C.F.R. 1.821(e) and (f)

Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper is a Reply under 37 C.F.R. 1.821(g) to
the "Notice to Comply with Requirements for Patent
Applications Containing Nucleotide Sequence and/or Amino
Acid Sequence Disclosures" mailed March 13, 2002.


U.S. Patent Application Serial No. 10/068,905,
was filed February 7, 2002, and included a paper copy of
the Sequence Listing in compliance with 37 C.F.R. 1.821(c).
Enclosed herewith is a computer-readable form (CRF) as
required by 37 C.F.R. 1.821(e).

The file on the CRF substantively identical to
the paper copy of the Sequence Listing previously filed for
U.S. Patent Application Serial No. 10/068,905. The content

of the paper copy of the Sequence Listing filed February 7, 2002 is the same as the content of the enclosed computer readable form of the Sequence Listing. The enclosed Sequence Listing CRF includes no new matter.

The enclosed CRF Sequence listing on a 1.44HD diskette is ASCII format, created February 4, 2002 in PatentIn v. 3.1 on an HP486/P75 computer operating in MS-DOS 6*. The Sequence Listing file "78490-7 Seq 04-02-02 v1.txt" was copied onto that diskette February 4, 2002.

Respectfully submitted,



Shannon L. Nebolsky, Reg. No. 41,217

Welsh & Katz, Ltd.
120 South Riverside Plaza
22nd Flcor
Chicago, Illinois 60606
(312) 655-1500

Enclosures

Diskette with CRF
Copy of Notice to Comply

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this Reply under 37 C.F.R. 1.821(g) Including Statements under 37 C.F.R. 1.821(e) and (f) together with the stated enclosures is being deposited with the United States Postal Service with Express Mailing Label No. EL 769846559 US in an envelope addressed to: Box Sequence, Commissioner for Patents, Washington D.C. 20231 on March 27, 2002.





UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILED/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/068,905	02/07/2002	Simon Lemaire	86366

Gerald T. Shekleton, Esq.
 Welsh & Katz, Ltd.
 22nd Floor
 120 S. Riverside Plaza
 Chicago, IL 60606



CONFIRMATION NO. 9394
FORMALITIES LETTER



OC000000007626068

Date Mailed: 03/13/2002


**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov



A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY